D-0316

DRUG2 trials

Sponsors

InventisBio Co., Ltd

Conditions

Advanced Non Small Cell Lung CancerEGFR T790MNSCLCSolid Tumor

Phase 1

D-0316 First Time in Patients Ascending Dose Study

CompletedNCT03452150

InventisBio Co., LtdAdvanced Non Small Cell Lung Cancer

Start: 2018-01-03End: 2020-12-31Updated: 2023-04-25

Phase 2

D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer

CompletedNCT03861156

InventisBio Co., LtdEGFR T790M, NSCLC, Solid Tumor

Start: 2019-02-28End: 2023-05-31Updated: 2024-04-09

Related Papers

Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial.

2024-07-272 citations

Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study.

2022-06-1821 citations

Phase I Trial of a Third Generation <i>EGFR</i> Mutant-Selective Inhibitor (D-0316) in Patients with Advanced Non-Small Cell Lung Cancer

The Oncologist2022-01-019 citations

Abstract CT170: D-0316 in patients with advanced T790M-positive EGFR-mutant non-small cell lung cancer who progressed on prior EGFR-TKI therapy: results from a phase II study (NCT03861156)

Cancer Research2021-07-011 citations